Skip to main content
. 2013 Dec 19;66(4):418–422. doi: 10.5173/ceju.2013.04.art6

Table 2. Recurrence and progression in the group of treated patients

Number of patients 243
Recurrence No 144 (59%)
Yes (all cases) 99 (41%)
Yes (≤1 x/year) 71 (29%)
Yes (>1 x/year) 28 (11%)
Progression (all cases) Yes 45 ( 18%)
Progression to muscle–invasive bladder cancer (MIBC) Yes 25 (10%)